Τίτλος:
Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Purpose: Introduction of cyclin-dependent inhibitors was a milestone in therapeutics for patients with estrogen receptor+/HER2− metastatic breast cancer. Despite the wide use of such agents and remarkable improvement of survival rates, drug-related adverse events are not yet fully characterized. We describe vitiligo-like lesions as a new adverse event occurring in patients with advanced breast cancer treated with cyclin-dependent inhibitors. Methods: We performed an international retrospective study including patients with advanced breast cancer who developed vitiligo-like lesions during treatment with cyclin-dependent kinases 4 and 6 inhibitors, in the period January 2018–December 2019. Patients > 18 years, both males and females, were recruited at six Dermatology Departments located in Italy (3), France (1) and Greece (2). We evaluated epidemiological and clinical characteristics, impact on quality of life and outcome of vitiligo-like lesions in patients treated with cyclin-dependent 4 and 6 inhibitors. The percentage of skin involved by vitiligo-like lesions was assessed using the Body Surface Area (BSA) score. Changes in patients’ quality of life were investigated through the evaluation of the Dermatology Life Quality Index (DLQI) questionnaire. Results: Sixteen women (median age: 62.5 years; range 40–79 years) treated with cyclin-dependent kinases 4 and 6 inhibitors for advanced breast cancer presented with vitiligo-like lesions during follow-up visits. Cutaneous lesions consisted of white, irregular macules and patches located mainly on sun-exposed areas in 11/16 patients or diffuse to the entire body surface in 5/16. Cutaneous lesions clearly impaired the quality of life of patients tested (DLQI ≥ 10). Conclusions: We present for the first time, to our knowledge, a case series of vitiligo-like lesions developing in patients with advanced breast cancer treated with cyclin-dependent kinases 4 and 6 inhibitors. We showed that such lesions further impair the patients’ quality of life and their treatment is challenging. © 2020, Springer Science+Business Media, LLC, part of Springer Nature.
Συγγραφείς:
Sollena, P.
Nikolaou, V.
Soupos, N.
Kotteas, E.
Voudouri, D.
Stratigos, A.J.
Fattore, D.
Annunziata, M.C.
Orlandi, A.
Di Nardo, L.
Apalla, Z.
Deilhes, F.
Romano, M.C.
Fabbrocini, G.
Sibaud, V.
Peris, K.
on behalf of the European Network for Cutaneous ADverse event of Oncologic drugs (ENCADO) group
Περιοδικό:
Breast Cancer Research and Treatment
Λέξεις-κλειδιά:
calcineurin inhibitor; corticosteroid; cyclin dependent kinase 4; cyclin dependent kinase 6; fulvestrant; letrozole; palbociclib; ribociclib, adult; advanced cancer; aged; Article; body surface; breast cancer; cancer hormone therapy; clinical article; clinical feature; Dermatology Life Quality Index; epidemiological data; female; human; multicenter study; phototherapy; quality of life; response evaluation criteria in solid tumors; retrospective study; treatment outcome; treatment refusal; treatment response; ultraviolet B radiation; very elderly; vitiligo; breast tumor; France; Italy; male; middle aged; vitiligo, Adult; Aged; Breast Neoplasms; Female; France; Humans; Italy; Male; Middle Aged; Quality of Life; Retrospective Studies; Vitiligo
DOI:
10.1007/s10549-020-05914-w
